Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Will Accept QT/QTc Comments Through Mid-February

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency is reopening the comment period for the International Conference on Harmonization QT prolongation draft guidances after a request from Wyeth. The comment period had ended in December.

You may also be interested in...



QT Prolongation Draft Guidance Urges Single Clinical Trial For Evaluation

The ECG trial should be early in clinical development (but not the first study) should be carried out in healthy volunteers and include a positive control group, FDA’s draft guidance says.

Pre-Clinical QT Prolongation Guidance Urges In Vitro, In Vivo Studies

FDA's 1draft guidance on preclinical evaluation of QT prolongation urges drug companies to initiate follow-up studies when nonclinical studies are inconsistent

Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint

FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.

Topics

UsernamePublicRestriction

Register

PS061018

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel